MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
基本信息
- 批准号:8520225
- 负责人:
- 金额:$ 31.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-25 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgeAntibodiesAntibody FormationAntigensBiological AssayBiological MarkersBiological ModelsBortezomibCancer EtiologyCapsidCell LineCellsCessation of lifeChronic Myeloid LeukemiaClinicalClinical InvestigatorCytostaticsDevelopmentDiagnosisDiseaseDisease ProgressionDisease remissionDoseDoxorubicinE2F transcription factorsEastern Cooperative Oncology GroupEnrollmentEnzyme-Linked Immunosorbent AssayEvolutionFundingGene ExpressionGenetic TranscriptionGenomicsGrowthHumanImmune responseImmunoblottingImmunoglobulin GImmunoglobulin MIn VitroIncidenceInfectionInvestigationKnock-outLarge T AntigenMalignant Epithelial CellMalignant NeoplasmsMeasuresMerkel CellsMerkel cell carcinomaModelingMolecularMonitorMonoclonal AntibodiesMusMutationNatural HistoryNude MiceOncogene ProteinsPathway interactionsPatientsPhasePhase II Clinical TrialsPolyomavirusPolyomavirus InfectionsPolyomaviruses Large T ProteinsPrevalenceProteasome InhibitorProtein FamilyProteinsProtocols documentationRandomizedReporterResearchRetinoblastomaRisk FactorsSerumSkinSkin CancerSmall Interfering RNAStagingSubfamily lentivirinaeSystemTestingTopoisomerase InhibitorsToxic effectTransgenic OrganismsTranslational ResearchTreatment ProtocolsViral ProteinsViral Tumor AntigensVirusVirus-like particleXenograft ModelXenograft procedurearmbasecancer cellchemotherapeutic agentchemotherapychromatin immunoprecipitationcytotoxicinhibitor/antagonistkillingsmouse modelnext generationpre-clinicalpromoterresearch studyresponsesurvivintherapy durationtumortumor xenografttumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Merkel cell carcinoma (MCC) is an aggressive human skin cancer causing more cancer deaths than chronic myelogenous leukemia in the US each year. Its incidence has climbed three-fold over the past 15 years to ~1500 cases per year. No cause for MCC was known until recently and no specific chemotherapy has been found to be effective. Using a genomic screen, we discovered Merkel cell polyomavirus (MCV) as a cause for 80% of MCC. We discovered tumor-specific MCV T antigen mutations are part of MCC tumor evolution, and we and our collaborators developed a highly specific and sensitive MCV VLP capsid ELISA, which was used to examine the natural history of MCV infection, including risk-factors, age-specific prevalence and primary infection. We developed monoclonal antibodies against MCV antigens in tumors. Through knockdown studies, we showed that T antigen expression is essential for MCC tumorigenesis and that MCV large T (LT) increases cellular survivin oncoprotein (BIRC5a). After identifying survivin to be a potential molecular chokepoint for MCC, we tested the Phase II survivin inhibitor, YM155, on both in vitro MCC cell lines and on human MCC xenografts in mice. YM155 is active as a single agent at nanomolar levels in killing or retarding growth of MCC. A multicenter ECOG protocol is now being developed by clinical investigators to examine the efficacy of YM155 among stage III/IV MCC patients based on these preclinical findings. This proposal is a renewal of our R01 to investigate biomarkers in MCV-induced cancers. In this proposal, we seek to leverage our findings to develop and optimize personalized therapy for MCC based on MCV infection: (1) We will first investigate the molecular basis for LT antigen activation of survivin, as well as YM155 inhibition of MCV LT-induced survivin expression. (2) We will optimize YM155 to try to induce durable tumor remission in MCC xenograft models by varying dose, duration of therapy and use of YM155 in combination with other chemotherapeutic agents. (3) We have developed a mouse lentivirus T antigen transduction expression system, which we will use to model mouse MCC development and to measure murine antibody responses to MCV T antigens. (4) We will determine whether patient antibodies to T antigens predict progression or regression of MCV-positive tumors in MCC patients undergoing YM155 treatment. Until recently MCC was both intractable and enigmatic. Our proposal shows that progress in translational science can rapidly proceed after a fundamental discovery: in this case, progress on MCC has advanced from cause to cure research in just over 3 years since MCV was first described. Funding this proposal will allow us to move onto the next generation of experiments to define at a molecular level how MCV causes cancer, how to best monitor MCC progression and how to optimally treat this virus-induced cancer.
描述(由申请人提供):默克尔细胞癌(MCC)是一种侵袭性人类皮肤癌,在美国每年导致的癌症死亡人数超过慢性髓性白血病。其发病率在过去15年中增加了三倍,达到每年约1500例。直到最近才知道MCC的原因,也没有发现有效的特异性化疗。使用基因组筛选,我们发现默克尔细胞多瘤病毒(MCV)作为80%的MCC的原因。 我们发现肿瘤特异性MCV T抗原突变是MCC肿瘤演变的一部分,我们和我们的合作者开发了一种高度特异性和敏感性的MCV VLP衣壳ELISA,用于检查MCV感染的自然史,包括风险因素,年龄特异性患病率和原发感染。我们开发了针对肿瘤中MCV抗原的单克隆抗体。通过敲低研究,我们发现T抗原表达对于MCC肿瘤发生是必不可少的,并且MCV大T(LT)增加细胞存活素癌蛋白(BIRC 5a)。在确定生存素是MCC的潜在分子阻塞点后,我们在体外MCC细胞系和小鼠中的人MCC异种移植物上测试了II期生存素抑制剂YM 155。YM 155作为单一药剂在纳摩尔水平下在杀死MCC或延缓MCC生长中是有活性的。临床研究人员正在开发一种多中心ECOG方案,以基于这些临床前发现来检查YM 155在III/IV期MCC患者中的疗效。 该提案是我们R 01的更新,以研究MCV诱导的癌症中的生物标志物。在本研究中,我们试图利用我们的发现来开发和优化基于MCV感染的MCC的个性化治疗:(1)我们将首先研究LT抗原激活生存素的分子基础,以及YM 155抑制MCV LT诱导的生存素表达。(2)我们将优化YM 155,以尝试通过改变剂量、治疗持续时间以及YM 155与其他化疗剂的组合使用来在MCC异种移植模型中诱导持久的肿瘤缓解。(3)我们已经开发了一种小鼠慢病毒T抗原转导表达系统,我们将使用它来模拟小鼠MCC的发展和测量小鼠对MCV T抗原的抗体应答。(4)我们将确定患者的T抗原抗体是否能预测接受YM 155治疗的MCC患者中MCV阳性肿瘤的进展或消退。直到最近,MCC还是一个既棘手又神秘的组织。我们的建议表明,转化科学的进展可以在基本发现后迅速进行:在这种情况下,自MCV首次被描述以来,MCC的进展在短短3年内就从病因发展到治愈研究。资助这项提案将使我们能够进入下一代实验,以在分子水平上确定MCV如何导致癌症,如何最好地监测MCC进展以及如何最佳地治疗这种病毒诱导的癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PATRICK S. MOORE其他文献
PATRICK S. MOORE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PATRICK S. MOORE', 18)}}的其他基金
Discovery and Characterization of New Human Cancer Viruses
新人类癌症病毒的发现和表征
- 批准号:
10360576 - 财政年份:2016
- 资助金额:
$ 31.67万 - 项目类别:
Discovery and Characterization of New Human Cancer Viruses
新人类癌症病毒的发现和表征
- 批准号:
10115622 - 财政年份:2016
- 资助金额:
$ 31.67万 - 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
- 批准号:
8017493 - 财政年份:2009
- 资助金额:
$ 31.67万 - 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
- 批准号:
7652877 - 财政年份:2009
- 资助金额:
$ 31.67万 - 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
- 批准号:
8215839 - 财政年份:2009
- 资助金额:
$ 31.67万 - 项目类别:
Role of a New Polyomavirus in Merkel Cell Carcinoma
新型多瘤病毒在默克尔细胞癌中的作用
- 批准号:
8694310 - 财政年份:2009
- 资助金额:
$ 31.67万 - 项目类别:
Role of a new polyomavirus in Merkel cell carcinoma
一种新的多瘤病毒在默克尔细胞癌中的作用
- 批准号:
8433428 - 财政年份:2009
- 资助金额:
$ 31.67万 - 项目类别:
MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
- 批准号:
8370549 - 财政年份:2008
- 资助金额:
$ 31.67万 - 项目类别:
MCC Tumor-Specific Biomarkers: Basis for Rational Therapy of Merkel Cell Carcinom
MCC 肿瘤特异性生物标志物:默克尔细胞癌合理治疗的基础
- 批准号:
8676455 - 财政年份:2008
- 资助金额:
$ 31.67万 - 项目类别:
Protein Biomarkers for a New Human Polyomavirus in AIDS-related Malignancies
艾滋病相关恶性肿瘤中新型人类多瘤病毒的蛋白质生物标志物
- 批准号:
7691836 - 财政年份:2008
- 资助金额:
$ 31.67万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Directed Grant